BofA raised the firm’s price target on United Therapeutics (UTHR) to $569 from $546 and keeps a Neutral rating on the shares. The company reported a “modest” revenue miss but beat on earnings per share and continued its practice of not offering forward revenue guidance, the analyst tells investors in a research note. The firm added that the Q4 revenue shortfall was largely on Tyvaso nebulizer and Q1 growth callout implies 2026 downward revenue re-basing.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- RBC says United Therapeutics TreSMI presents ‘material risk’ to MannKind
- Leerink sees MannKind selloff as ‘overreaction’ to headline news
- Liquidia reaction on United Therapeutics’ TreSMI reveal ‘overdone,’ says Needham
- H.C. Wainwright sees MannKind selloff ‘potentially resetting’ value proposition
- Balanced Hold on United Therapeutics Amid Near-Term Pressure and Key Late-Stage Pipeline Readouts